Villarreal, Alcibiades E.
https://orcid.org/0000-0002-6684-0593
Mayo Clinic
Instituto de Investigaciones Científicas y Servicios de Alta Tecnología
Citations 2
Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic
Lista, Simone , Vanderstichele, Hugo, Posner, Holly, Hall, James , Johnson, Leigh , Fong, Y L, Luthman, Johan, Jeromin, Andreas, Batrla‐Utermann, Richard, Villarreal, Alcibiades E. , Britton, Gabrielle B. , Snyder, Peter J. , Henriksen, Kim , Grammas, Paula , Gupta, Veer Bala , Martins, Ralph N. , Hampel, Harald , Area, Biofluid Based Biomarker Professional Interest, O’Bryant, Sid E. , Mielke, Michelle M. , Rissman, Robert A. , Zetterberg, Henrik , Lewczuk, Piotr , Area, Biofluid Based Biomarker Professional Interest
Alzheimer's & Dementia | November 18, 2016 | Volume: 13 | Issue: 1 | Pages: 45-58
AbstractThe last decade has seen a substantial increase in research focused on the identification of blood‐based biomarkers that have utility in Alzheimer's disease (AD). Blood‐based biomarkers have significant advantages of being time‐ and cost‐efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood‐based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public‐private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.
A blood screening test for Alzheimer's disease
O’Bryant, Sid E. , Hall, James , Villarreal, Alcibiades E. , Britton, Gabrielle B. , Quiceno, Mary , Cullum, C. Munro , Graff‐Radford, Neill R., Edwards, Melissa , Johnson, Leigh , Graff‐Radford, Neill R., O'Bryant, Sid
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | June 26, 2016 | Volume: 3 | Issue: 1 | Pages: 83-90
AbstractIntroductionThis study combined data across four independent cohorts to examine the positive and negative predictive values of an Alzheimer's disease (AD) blood test if implemented in primary care.MethodsBlood samples from 1329 subjects from multiple independent, multiethnic, community‐based, and clinic‐based cohorts were analyzed. A “locked‐down” referent group of 1128 samples was generated with 201 samples randomly selected for validation purposes. Random forest analyses were used to create the AD blood screen. Positive (PPV) and negative (NPV) predictive values were calculated.ResultsIn detecting AD, PPV was 0.81, and NPV was 0.95 while using the full AD blood test. When detecting mild cognitive impairment, PPV and NPV were 0.74 and 0.93, respectively. Preliminary analyses were conducted to detect any “neurodegenerative disease”. The full 21‐protein AD blood test yielded a PPV of 0.85 and NPV of 0.94.DiscussionThe present study creates the first‐ever multiethnic referent sample that spans community‐based and clinic‐based populations for implementation of an AD blood screen.